Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT07676006
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given to any patient without needing to be customized. The cells are designed to target two proteins, CD33 and CD70, found on leukemia cells. The study will evaluate safety, the right dose, and how long the cells last in the body, with some participants also receiving a drug called sirolimus to see if it helps the cells work better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GT737 injection (off-the-shelf iNKT cells targeting CD33 and CD70)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia who have run out of standard therapies.
What could go wrong
This is a very early, small study (36 people) focused on safety and dosing. The therapy may not work, and side effects could be serious, including immune reactions or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 450018, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact